A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
NeoCerebellar Degeneration Paraneoplastic Profile with Recombx®
Test Code91623
CPT Codes
83520 (x7), 86341
Includes
Amphiphysin Antibody Test
GAD65 Antibody Test, Recombx
MaTa Autoantibody Test, Recombx
CV2 Antibody Test, Recombx
Hu Autoantibody Test, Recombx
Ri Autoantibody Test, Recombx
Yo Autoantibody Test, Recombx
Zic4 Antibody Test
GAD65 Antibody Test, Recombx
MaTa Autoantibody Test, Recombx
CV2 Antibody Test, Recombx
Hu Autoantibody Test, Recombx
Ri Autoantibody Test, Recombx
Yo Autoantibody Test, Recombx
Zic4 Antibody Test
Preferred Specimen
2 mL serum
Minimum Volume
0.5 mL
Instructions
Serum must be separated from cells within 48 hours of collection.
Please label each specimen tube with two forms of patient identification. These forms of identification must also appear on the requisition form.
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: 72 hours
Refrigerated: 28 days
Frozen: 28 days
Refrigerated: 28 days
Frozen: 28 days
Methodology
Automated Nanoliter Scale Immunoassay • Enzyme Linked Immunosorbent Assay (ELISA)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Athena Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Mon, Wed, Fri; Report available: 7-10 days
Clinical Significance
Anti-CV2, anti-Hu, anti-Ma, anti-Ta, anti-Ri, anti-Yo, anti-Zic4 antibodies, and anti-GAD65 are found in patients with acute or subacute symptoms of cerebellar degeneration including gait ataxia, nystagmus and/or dysarthria, and opsoclonus/myoclonus. This semi-quantitative assay may be useful in monitoring therapeutic responses in select cases.